A Study of L19TNF Plus Lomustine in People With Brain Cancer

Full Title

A Dose Optimization Study for L19TNF in Combination with Lomustine in Patients with Glioblastoma at Progression or Recurrence

Purpose

In this study, researchers want to find the best doses of L19TNF and lomustine for people with brain cancer. The people in this study have glioblastoma that keeps growing or came back after treatment.

L19TNF works with the immune system to destroy cancer cells. It is given intravenously (by vein). Lomustine is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have glioblastoma that keeps growing or came back after treatment.
• Have completed previous glioblastoma therapies at least 4 weeks before getting the study treatment.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Lauren Schaff’s office at 212-610-0485.